Trial Profile
PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer: a Single Arm Phase II Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; BAT-1306 (Primary) ; Celecoxib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PCOX study
- 20 Mar 2023 Planned number of patients changed from 27 to 29.
- 20 Mar 2023 Planned End Date changed from 31 Aug 2021 to 31 Aug 2025.
- 25 Jun 2020 Planned number of patients changed from 54 to 27.